Armstrong Paul A, Back Martin R, Bandyk Dennis F, Johnson Brad L, Shames Murray L
Division of Vascular and Endovascular Surgery, University of South Florida School of Medicine, 4 Columbia Drive, Tampa, FL 33606, USA.
J Vasc Surg. 2007 Jul;46(1):71-8. doi: 10.1016/j.jvs.2007.02.058.
The complexity of variables associated with vascular surgical site infections (VSSI) often contribute adversely to reinfection, limb salvage, and mortality rates. This report details our experience with the selective use of a sartorius muscle flaps (SMF) as part of an overall treatment strategy focused on staged surgical debridement (SSD) to control prosthetic graft bed infection prior to a graft preservation or revision plan.
From our vascular registry, we identified 422 VSSI of which 89 (21%) had SMF for 24 aorto-bifemoral (ABF), 19 extra-anatomic bypasses (EAB), 34 infrainguinal bypasses, and 12 combined inflow/outflow reconstructions. All 86 patients had Szilagyi grade III prosthetic (Dacron-36, polytetrafluoroethylene [PTFE]-50) graft infections. The treatment algorithm included: SSD, culture-directed parenteral antibiotics, graft preservation (n = 3), or reconstruction (graft excision/EAB, n = 4; rifampin-bonded PTFE, n = 22; autologous conduit, n = 57) based on microbiology and consideration for SMF for extensive soft tissue defects (n = 43) or non-sterilized graft beds (n = 40). Analysis of microbiology, recurrent infection, vascular reconstruction, limb salvage, and mortality was completed over a mean follow-up of 52 months (range: 12 to 132 months).
Thirty-day mortality was 2% with two aortic graft infections dying from sepsis. Survival by life table analysis at 1, 3, and 5 years was 94%, 92%, and 90%, respectively. Wound isolates were most commonly gram positive organisms (n = 58, 65%), with gram negative isolates and mixed infections accounting for 19% and 10%, respectively. A single recurrent groin infection was documented at 30 days. Freedom from recurrent infection (n = 6) at 1 and 5 years was 98% and 92% by life tables. Methicillin-resistant Staphylococcus aureus (MRSA) was involved for 50% of reinfections. No amputations were attributable to uncontrolled VSSI and graft patency was 100% in surveillance monitored patients.
These results suggest that selective utilization of SMF as part of SSD treatment plan in an attempt to achieve graft bed sterilization can effectively control the complex infectious process allowing for potentially improved outcomes for in situ or preservation graft salvage techniques. Lifelong graft surveillance is recommended.
与血管手术部位感染(VSSI)相关的变量复杂性常常对再感染、肢体挽救和死亡率产生不利影响。本报告详细介绍了我们选择性使用缝匠肌瓣(SMF)的经验,这是整体治疗策略的一部分,该策略侧重于分期手术清创(SSD),以在进行移植物保存或翻修计划之前控制人工血管移植床感染。
从我们的血管登记处,我们识别出422例VSSI,其中89例(21%)使用了SMF,包括24例主动脉-双股动脉(ABF)、19例解剖外旁路(EAB)、34例腹股沟下旁路以及12例联合流入/流出重建。所有86例患者均有Szilagyi III级人工血管(涤纶-36,聚四氟乙烯[PTFE]-50)感染。治疗方案包括:SSD、根据培养结果使用肠外抗生素、移植物保存(n = 3)或重建(移植物切除/EAB,n = 4;利福平结合PTFE,n = 22;自体血管,n = 57),具体取决于微生物学情况,并考虑对广泛软组织缺损(n = 43)或未消毒的移植床(n = 40)使用SMF。在平均52个月(范围:12至132个月)的随访期内,完成了微生物学、复发性感染、血管重建、肢体挽救和死亡率的分析。
30天死亡率为2%,2例主动脉移植物感染患者死于败血症。通过生命表分析,1年、3年和5年的生存率分别为94%、92%和90%。伤口分离出的微生物最常见的是革兰氏阳性菌(n = 58,65%),革兰氏阴性菌分离株和混合感染分别占19%和10%。记录到1例30天时复发性腹股沟感染。通过生命表分析,1年和5年无复发性感染(n = 6)的概率分别为98%和92%。耐甲氧西林金黄色葡萄球菌(MRSA)导致了50%的再感染。没有截肢是由于VSSI控制不佳导致的,在接受监测的患者中,移植物通畅率为100%。
这些结果表明,选择性使用SMF作为SSD治疗计划的一部分,试图实现移植床消毒,可有效控制复杂的感染过程,可能改善原位或保存移植物挽救技术的预后。建议进行终身移植物监测。